Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Chinese rheumatoid arthritis (RA) drug market will triple between 2006 and 2011. According to the new Emerging Markets report entitled Rheumatoid Arthritis in China, this growth will be fueled by a growing drug-treated population, increased access to health insurance and greater patient spending power.

The report also finds that need still exists for inexpensive, highly effective drug therapies in the Chinese RA market. Although the cost of RA therapy in China is lower than in the United States, Europe or Japan, many patients cannot pay for treatment because out-of-pocket costs are a significantly greater percentage of disposable income than in the West. The high cost of some RA therapies, such as biological agents and agents available only in costly Western versions, prevents patients from receiving these drug therapies, especially in rural areas of China.

"Chinese health authorities have launched several initiatives to promote awareness and early treatment of RA," said Dancella Fernandes, Ph.D., analyst at Decision Resources. "These initiatives also aim to move treatment away from the traditional Chinese medicines to newer, more-effective treatments and disease-modifying therapy. These initiatives will increase RA diagnosis and drug-treatment rates in China and present an opportunity for multinational companies to reach a larger patient population."

About Emerging Markets -- China

Emerging Markets - China is the first and only syndicated report series focusing on high-growth emerging markets with comprehensive disease-specific analysis. With these reports, biopharmaceutical companies can accomplish the following:

  -- More accurately assess their commercial opportunity for Western brands      in key pharmaceutical markets of China - Beijing, Shanghai, Guangzhou -      and in the high-growth second-tier markets of Tianjin, Wuhan, Nanjing,      Hangzhou, and Jinan.   -- Understand the physician treatment patterns and drivers of choice in      key first- and second-tier cities based on primary research.   -- Gain a clear perspective of the Chinese 5-year market forecast at the      drug level, broken out by urban and rural areas, and by sales from      multinational and Chinese-based companies.    About Decision Resources 

Decision Resources, Inc., (www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Crohn's Disease Drug Market Will More Than Double to $4 Billion by 2016, with Near-Term Growth Driven by Remicade and Humira

View Now